Therapeutic effects of a small molecule agonist of the relaxin receptor ML290 in liver fibrosis

Fibrosis is an underlying cause of cirrhosis and hepatic failure resulting in end stage liver disease with limited pharmacological options. The beneficial effects of relaxin peptide treatment were demonstrated in clinically relevant animal models of liver fibrosis. However, the use of relaxin is pro...

全面介紹

Na minha lista:
書目詳細資料
發表在:FASEB J
Main Authors: Kaftanovskaya, Elena M., Ng, Hooi Hooi, Soula, Mariluz, Rivas, Bryan, Myhr, Courtney, Ho, Brian A., Cervantes, Briana A., Shupe, Thomas D., Devarasetty, Mahesh, Hu, Xin, Xu, Xin, Patnaik, Samarjit, Wilson, Kenneth J., Barnaeva, Elena, Ferrer, Marc, Southall, Noel T., Marugan, Juan J., Bishop, Colin E., Agoulnik, Irina U., Agoulnik, Alexander I.
格式: Artigo
語言:Inglês
出版: Federation of American Societies for Experimental Biology 2019
主題:
Research
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC6988856/
https://ncbi.nlm.nih.gov/pubmed/31419161
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1096/fj.201901046R
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍